Revenue Breakdown
Composition ()
No data
Revenue Streams
Novavax Inc (NVAX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Licensing Royalties And Other, accounting for 69.8% of total sales, equivalent to $97.31M. Another important revenue stream is Product. Understanding this composition is critical for investors evaluating how NVAX navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Novavax Inc maintains a gross margin of 78.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -7.19%, while the net margin is -6.80%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively NVAX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, NVAX competes directly with industry leaders such as MBX and QURE. With a market capitalization of $1.72B, it holds a leading position in the sector. When comparing efficiency, NVAX's gross margin of 78.00% stands against MBX's N/A and QURE's 93.85%. Such benchmarking helps identify whether Novavax Inc is trading at a premium or discount relative to its financial performance.
